cyrilzakka/clinical-trials huggingface dataset:
Routine Pathological Examination of Hernia Sac; Is it a Workload or Necessary?

Routine microscopic examination of the hernia sac is controversial. While some centers do not recommend a routine microscopic examination in inguinal hernias in adult patients, they recommend them in abdominal wall hernias. The investigators aimed to discuss the pathology results and unexpected histopathological findings who underwent abdominal wall and inguinal hernia operation in the light of the literature.

The hernia is defined as the passage of an organ or tissue from one anatomical region to another. Hernia sacs are sent to the pathology department, although there is a difference between clinics. Routine microscopic examination of the hernia sac is controversial. While some centers do not recommend a routine microscopic examination in inguinal hernias in adult patients, they recommend them in abdominal wall hernias. Here, the investigators aimed to discuss the pathology results and unexpected histopathological findings who underwent abdominal wall and inguinal hernia operation in the light of the literature. Patients who have operated hernia and sent hernia sac for histopathological examination were retrospectively screened. Emergency and elective operated patients were included. Hernia repairs without pathology were excluded from the study. Patients' gender, age, operation notes, and pathology results were analyzed. Pathology results were analyzed in two groups as expected findings and unexpected findings. In our study, the probability of encountering an unexpected pathological result was found to be quite low in the pathological evaluation of the hernia sac. Although it may cause additional workload and cost, all hernia sacs should be sent to routine pathological examination. The investigators believe that making savings in these areas through further investigation after the decision of the pathologist.

Eligibility Criteria:
Inclusion Criteria:

* Emergency operated patients
* Elective operated patients

Exclusion Criteria:

* Hernia repairs without pathology examinations
Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

Primary Phase I:To determine dose limiting toxicities and maximum tolerated dose (MTD) of the oral administration of hydroxychloroquine (HCQ) in conjunction with transarterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC). A conventional 3+3 design will be utilized. Primary Phase II: To evaluate the complete response rate in a cohort of patients treated at the MTD, A Simon's Optimal Two-stage design will be utilized.


Eligibility Criteria:
Inclusion Criteria:

* Patient capable of giving informed consent
* Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods (Pathologically confirmed HCC by biopsy or HCC 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced MRI or CT or Lesion greater than 2 cm with probable imaging features of HCC and imaging findings of cirrhosis and/or portal hypertension or a serum alphafetoprotein (AFP) greater than 200 mg/mL.
* Patient not candidate for orthotopic liver transplantation at the Hospital of the University of Pennsylvania based on review of patient imaging and history at multidisciplinary Hepatic Tumor Conference at the Hospital of the University of Pennsylvania.
* Age 18 years old
* Albumin 2.4 g/dL; Total bilirubin 2 mg/dL; INR 1.5
* Creatinine 2.0 mg/dL, AST 121 IU/L; ALT 189 IU/L
* Child-Turcotte-Pugh Classification A or B
* Eastern Clinical Oncology Group performance status 0 or1.

Exclusion Criteria:

* Prior TACE
* Active GI hemorrhage within 2 weeks of study enrollment
* Ascites refractory to medical therapy
* Contraindication to receiving HCQ or TACE
* Unilobar HCC
* Contraindication to contrast enhanced MRI (i.e. unable to undergo follow-up imaging)
* Women who are pregnant
* Participation in another concurrent treatment protocol
Efficacy and Safety of Sodium Heparin (Eurofarma)

The objective of this study is to verify, through a randomized, single-blind, multicentre, parallel and comparative study, the effectiveness of heparin sodium of porcine origin in patients undergoing heart surgery at that require the aid of cardiopulmonary bypass, through the control of hemostasis during and after surgery, based on the strengths of markers of coagulation TCA, TTPA, Anti-Xa, heparin bioavailable and loss of excessive blood (bleeding) at the end of the surgery.


Eligibility Criteria:
Inclusion Criteria:

* Patients who agree with all aspects of the study and sign the FICT;
* Patients of both sexes;
* Patients aged above 18 years;
* Patients with cardiac surgery and requiring movement; AND
* Extracorporeal.

Exclusion Criteria:

* Patients with hematological disorders that compromise the surgical changes (eg myeloproliferative syndromes, anemia Hb \<11.0 g / dL,
* Platelets \< 150,000 mm3);
* Patients with disorders of hemostasis (INR\> 1.40) (rTTPA\> 1.40);
* Patients with renal dysfunction (creatinine\> 1.50);
* Patients with deep hyperthermia;
* Liver disease (AST and ALT\> 2 times that of the reference value);
* Patients with a history of allergy to heparin or protamine;
* Patients with history of heparin-induced thrombocytopenia;
* Tables infection (eg endocarditis, infection of immune human (HIV), hepatitis B and C, septicemia and pneumonia);
* Reoperations;
* Use of antiplatelet (clopidogrel and ticlopidine) for less than 7 days;
* Use of acetylsalicylic acid is less than 5 days;
* Use of low molecular weight heparin for less than 24 hours; OR
* Use of non-fractioned heparin for less than 12 hours.
Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis

This study is to evaluate available data in Iraqi patients with ankylosing spondylitis on Enbrel treatment with regards to the impact of early treatment using data from the Baghdad Teaching Hospital registry


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed AS patients.

  * 18 years old
* Did not receive previous biological treatment for any reason

Exclusion Criteria:

* Patients previously or currently treated with other biological therapies.
* Use of etanercept for less than 1 year duration.
Anosmia and / or Ageusia and Early Corticosteroid Use

Time to recover of Anosmia and / or ageusia and early corticosteroid use

In a study of dexamethasone kinetics in two groups of 15 patients with community-acquired pneumonia, one group was treated with dexamethasone 6 mg/day by mouth and the other with 4 mg/day intravenously. The apparent volume of distribution was 1 L/kg in both groups, but the half-life after oral administration was approximately 7 hours, and after intravenous administration 9 hours. The bioavailability of oral dexamethasone was 81% (95% CI = 54-121%). However, the biological half-life of dexamethasone is much longer, of the order of 36-54 h compared with 18-36 h for prednisolone.

Time to recover of Anosmia and / or ageusia and early corticosteroid use

Eligibility Criteria:
Inclusion Criteria:

* Any case with COVID-19
* Age more than or equal to 18 years
* Mild to moderate severity

Exclusion Criteria:

* Diabetes
* Any contra-indication for the interventional drug
* Mentally disabled cases
A Pilot Registry for Ultrasound-guided Pharmacopuncture

A pilot study of prospective resigstry to evaluate the safety and efficacy of ultrasound-guided pharmacopuncture for spinal disorders

This study aims to evaluate the safety and efficacy of ultrasound-guided pharmacopuncture by collecting information on adverse reactions, efficacy assessment variables, and treatment methods from patients diagnosed with spinal disorders who have undergone ultrasound-guided pharmacopuncture treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Individuals diagnosed with spinal disorders (M code and S code based on KCD criteria)
2. Outpatients scheduled for ultrasound-guided pharmacopuncture treatment
3. Individuals aged 19 years or older and under 70 years
4. Individuals who agree to participate in the clinical study and voluntarily sign the consent form

Exclusion Criteria:

1. Individuals who are unable to complete the consent form
2. Individuals who are deemed unsuitable for participation in the clinical study by the researcher
5-year Clinical Evaluation of Cavity Lining on the Restoration

The purpose of this double-blind, randomized trial is to compare the clinical performance of a composite restorations in root surface carious lesions with or without resin modified glass ionomer lining.

Thirty-nine patients with at least one pair of equivalent root caries lesions and a mean age of 39.6 years (range 18-65 years; median 39 years) were enrolled in this study. After caries removal, the depth, length, and width of the cavity were measured. Lesions in the same patient was randomly divided into two groups, and the dentin surfaces were either lined with resin-modified glass ionomer liner (Glass liner II, Willmann \& Pein GmbH Dental, Barmstedt, Germany) or not. All cavities were restored with nanohybrid composite resin (Clearfil Majesty Esthetic, Kuraray, Tokyo, Japan). A total of 100 restorations (50 lined, 50 unlined) were placed according to manufacturer's instructions. The restorations will be evaluated at baseline and at 6, 12, 24, 36, 48 months and 5-year after placement using the modified Haveman Criteria for marginal adaptation, anatomic form, marginal staining, anatomic form, caries in adjacent tooth structure, caries at the cavosurface margin and sensitivity. Statistical analysis will be conducted using the Chi- Square, Fisher's Exact, Mann Whitney-U and Cochran Q tests at a significance level of 5% (P \< 0.05).

Eligibility Criteria:
Inclusion Criteria:

* Non-hospitalized, healthy patients that were seeking dental treatment for caries lesions on the root surface

Exclusion Criteria:

* Patients who were under the age of 18 years
* Complex medical history
* Severe or chronic periodontitis
* Extreme carious activity
* Heavy bruxism
* Very deep or superficial carious lesions
* Previously restored and abutment teeth
Effectiveness of Pressure Release Technique in Patients With Chronic Low Back Pain

A Pressure Release Technique will be test in patient with low back pain compared to a sham


Eligibility Criteria:
Inclusion Criteria:

* chronic low back pain at least 6 months

Exclusion Criteria:

* hernia, neurologic pain
Mortality Reductions Based on AUD/Heavy Alcohol Use, HIV Risk, and Cardiovascular Risk

The purpose of this research study is to investigate if a personalized intervention including parts such as navigation (focus on patient outreach efforts, missed and completed encounters), personalization (individual health benefits) and compensation (value health-related costs borne by patients) will help people reduce their chances of dying from preventable causes, including heart attacks, strokes, drinking alcohol, substance abuse, HIV, and other conditions.


Eligibility Criteria:
Inclusion Criteria:

1. Age 35 to 64
2. Low SES (≤ $38,000 annual income, based on 2019 20th percentile NYC income, adjusted for family size)
3. Expected mortality ≥1% per year (based on age, sex, race/ethnicity), with ≥1 of the following contributors:

   1. 10-year cardiovascular risk ≥10% (assessed by ASCVD risk tool)
   2. Heavy alcohol consumption (defined using SAMHSA binge drinking definition, drinking \>4 standard drinks for men and \>3 standard drinks for women on same occasion in past month)
4. Willing to be navigated to Health and Hospitals Corporation of New York health system.
5. Ability to provide written informed consent in English or Spanish

Exclusion Criteria:

1. Receives regular care elsewhere than Health and Hospitals Corporation of New York
2. Already diagnosed with high mortality-condition(s) that are not included in the simulation model.
Effect of an Environmental Health Education Program on Pregnant Women in Order to Reduce Endocrine Disruptor Exposition

Endocrine disruptors are known as a cancer cause. On pregnant women, it can induce major foetal pathology and impact growth.

Among those molecules, bisphenol-A (BPA) is a plasticizer that can be found on cans and water.

Through a prevention program, the investigators tried to warned pregnant women on endocrine disruptors exposition risks. The goal here is to assess the effectiveness of this program on their fresh products consumption.


Eligibility Criteria:
Inclusion Criteria:

* Patients over 18
* Patients living in Poitiers or city around (near the immersive environment)
* Patients on pregnancy and who declared their pregnancy to the authority
* Patients who planned to give birth in Poitiers's hospital, Châtellerault's hospital or Clinique Fief de Grimoire, in Poitiers.
* Patients giving her agreement

Exclusion Criteria:

* Patients planning to move during the study
* Patients under legal protection
* Patients expecting twins
* Patients unable to speak french
* Patients willing to give birth in another hospital than those mentionned before
Depolarising Electrical Skin Stimulation in Neuropathic and Postoperative Pain

The aim of the study is to evaluate voltage gated sodium channel (NaV1.7) dependent pain phenomena in neuropathic pain and chronic postoperative pain.

Sinus-like electrical stimulation may depolarize unmyelinated skin nociceptors involving NaV1.7 channels. In this case electrical stimulation may provoke pain already with very low currency intensity which normally not provoke pain in healthy subjects. This may be predictive for pain relief due to the sodium channel blocker lidocaine 5% patch.

The study will characterize pain states in peripheral neuropathic pain as well as within the painful scar in chronic postoperative pain with regard to the involvement of NaV1.7 channels.

In addition, the pain site in chronic postoperative pain (scar) will be characterized by laser-evoked potentials (LEP) and quantitative sensory testing (QST).

Pain related questionnaires will be obtained.

Eligibility Criteria:
Inclusion Criteria:

* Group (1) patients with neuropathic pain
* Group (2) patients with chronic postoperative pain

Exclusion Criteria (both Groups):

* severe psychiatric disorder requiring hospitalisation in the past
* any neurological disease other than the pain diagnosis
A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis

This multicenter, open-label, single arm long-term extension of study WA19926 will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with early, moderate to severe rheumatoid arthritis who have completed the WA19926 core study. Eligible participants will receive tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Participants who complete WA19926 core study (visit at Week 104 and two follow-up telephone visits) and who may benefit from study drug treatment according to the Investigator's assessment
* No current or recent adverse event or laboratory finding preventing the use of the study drug dose of tocilizumab 8 mg/kg at baseline visit
* Receiving treatment on an outpatient basis
* Females of child-bearing potential must agree to use at least one adequate method of contraception as defined by protocol during the treatment period

Exclusion Criteria:

* Pregnant women
* Participants who have prematurely withdrawn from the WA19926 study for any reason
* Treatment with any investigational agent or cell depleting therapies since last administration of study drug in the WA19926 core study
* Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL)1 agent, or a T-cell co-stimulation modulator since the last administration of the study drug in the WA19926 core study
* Immunization with a live/attenuated vaccine since the last administration of study drug in the WA19926 core study
* Diagnosis since visit at Week 104 of the core WA19926 study of rheumatic autoimmune disease other than rheumatoid arthritis
* Diagnosis since visit at Week 104 of the core WA19926 study of inflammatory joint disease other than rheumatoid arthritis
* Evidence of serious uncontrolled concomitant disease or disorder
* Known active or history of recurrent infection
* Current liver disease as determined by Investigator
Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care Hospital

This study is to investigate the recent epidemiological trends and the treatment outcome in terms of the length of hospital stay, the relevant renal and neurological side effects, risk factors for developing these side effects, the selection of more resistant pathogens under therapy as well as the incidence of Clostridium difficile infections under treatment.

Increasing resistance among Enterobacterales to beta-lactam antibiotics is globally a major concern in the antibiotic resistance crisis. In gram-negative bacteria it evolves primarily through the production of beta-lactamases that allow the rapid hydrolysis of common antibiotics - most notably 3rd generation cephalosporins. Particularly, the production of Ambler class C beta-lactamase (AmpC) is a very concerning and unique resistance mechanism as so called derepressed mutants can be induced during treatment. Information on recent epidemiological trends as well as comparative information about the treatment strategies (cefepime versus piperacillin/tazobactam versus carbapenems) for infections with AmpC-producing Enterobacterales in Switzerland is still lacking. This study is to investigate the recent epidemiological trends and the treatment outcome in terms of the length of hospital stay, the relevant renal and neurological side effects, risk factors for developing these side effects, the selection of more resistant pathogens under therapy as well as the incidence of Clostridium difficile infections under treatment.

Eligibility Criteria:
Inclusion Criteria:

* Patients with detection of AmpC beta-lactamase producing Enterobacterales

  1. In a blood culture (any ward)
  2. In a clinical sample of the lower respiratory tract (only intensive care unit)

Exclusion Criteria:

* Patients with documented refusal of subsequent use of their data
Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy

To investigate the efficacy and safety of modified deep lateral wall decompression and/or medial wall decompression for Moderate-to-severe Grave's Ophthalmopathy.

The purpose of the study is to evaluate the effectiveness and complications of modified deep lateral wall decompression and medial wall decompression, in order to develop a standardized technical approach to the treatment of Moderate-to-severe Grave's Ophthalmopathy.

Eligibility Criteria:
Inclusion Criteria:

1. EUGOGO/NOSPECS grade was moderate-to-severe thyroid associate ophthalmopathy;
2. CAS≤3 score;
3. stable thyroid function for at least 6 months;
4. able and willing to participate in clinical trials and ensure regular follow-up;

Exclusion Criteria:

1. any uncontrollable clinical problems (severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant tumors);
2. B-ultrasound or CT, MRI found other diseases causing exophthalmos (intraorbital space occupying lesion, inflammatory pseudotumor, neurofibroma, etc.);
3. uveitis, glaucoma, high myopia, diabetic retinopathy and other eye diseases
4. those who were considered by the researchers to be excluded
Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects

The purpose of this study is to determine whether the drug UE2343, a potential treatment for Alzheimer's Disease (AD), is effective by assessing safety, tolerability, pharmacokinetics and pharmacodynamics in a Multiple Ascending Dose Study. Protocol amendments to the study will examine any food effect and determine if the drug penetrates the Blood-Brain Barrier.

Part 1 of this study is a double-blind, randomised, placebo-controlled, multiple ascending dose study to assess the safety, tolerability, PK and PD in healthy participants dosed twice daily at levels of 10, 20 and 35mg for 10 days.This part of the study will recruit 3 groups of 8 participants each.

Part 2 is a cross-over study to assess the effects of food on the PK of UE2343 in healthy participants dosed with two single doses at a level decided from Part 1. This part of the study will recruit a total of 12 participants.

Part 3 seeks to determine the PK of the UE2343 in CSF of healthy participants dosed twice daily for 4 days with a dose level determined from Part 1 and 2. This part of the study will recruit 4 participants.

Strategies to ensure adherence to the study include the requirement that participants remain at the clinical research facility for the duration of their participation in the study; drug accountability checks (i.e. reconciliation of used and unused capsules) by an independent clinical research associate; and administration of the capsules to the participant by a member of the study site team.

Eligibility Criteria:
Inclusion Criteria:

* Willing to use specified contraception
* BMI within specified range
* No clinically significant abnormalities in the results of laboratory evaluations at Screening and Day -1.

Exclusion Criteria:

* Abnormal medical history, including history of dementia
* No significant allergic reactions
* No prior drug or alcohol abuse
* Use of regular prescribed medication
Effects of Abrocitinib Treatment on Skin Barrier Function

Effects of abrocitinib treatment of atopic dermatitis on skin barrier function.

Open-label, non-randomized, single-arm, 12-weeks observational clinical and translational study

Eligibility Criteria:
Inclusion Criteria:

1. Written informed consent obtained from the subject prior to performing any protocol-related pro-cedures, including screening evaluations
2. Age ≥ 18 years at time of study entry.
3. Diagnosis of chronic atopic dermatitis for at least 1 year prior to enrollment based on American Academy Criteria
4. Eczema Area and Severity Index (EASI) score ≥12 at baseline visit (Week 0)
5. Investigator Global Assessment (IGA) ≥3 at baseline visit (Week 0)
6. Subject is willing and able to comply with the protocol for the duration of the study
7. Subject receives abrocitinib by the treating dermatologist within routine care

Exclusion Criteria:

1. 1. Subject is unable to provide written informed consent or comply with the protocol
2. Concurrent enrolment in another clinical trial where the subject is receiving an IMP or participation in another clinical trial with investigational product during the last 30 days before inclusion or 7 half-lives of previously used trial medication, whichever is longer.
3. Active dermatologic conditions that may confound the diagnosis of AD or would interfere with as-sessment of treatment, such as scabies, cutaneous lymphoma, or psoriasis.
4. Known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of severity of AD.
5. Having used systemic immunosuppressive/immunomodulating therapy (e.g. systemic corticoster-oids methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, JAK inhibitors) or tanning beds or phototherapy during any week within the 4 weeks or receipt of any marketed biologic ther-apy (e.g., dupilumab, tralokinumab) within 3 months or 5 half-lives, whichever is longer, prior to baseline
6. Treatment of selected marker skin areas (non-lesional skin at volar forearm and extensor forearm, lesional skin) with topical corticosteroid or topical calcineurin inhibitor 1 week prior to baseline visit and throughout the study.
7. Treatment of skin areas of examination with emollients 24 hours prior to baseline visit and throughout the study.
8. Involvement in the planning and/or conduct of the study.